Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATM R2032K |
| Therapy | Enzalutamide + Talazoparib |
| Indication/Tumor Type | prostate cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM R2032K | prostate cancer | sensitive | Enzalutamide + Talazoparib | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (TALAPRO-3) that supported FDA approval, Talzenna (talazoparib) plus Xtandi (enzalutamide) improved median progression-free survival compared to placebo (77% vs 56%, HR 0.48, p<0.001) in metastatic androgen pathway modulation-sensitive or -naive prostate cancer patients harboring alterations in homologous recombination repair genes as detected by approved assays, including ATM R2032K (PMID: 42223064; NCT04821622). | 42223064 detail... detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Full reference... | ||
| Talzenna (talazoparib) FDA Drug Label | Full reference... | |
| (42223064) | PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer. | Full reference... |